Comparative Pharmacology
Head-to-head clinical analysis: CANASA versus DIPENTUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANASA versus DIPENTUM.
CANASA vs DIPENTUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine (5-aminosalicylic acid) is an anti-inflammatory agent that inhibits prostaglandin and leukotriene synthesis, scavenges reactive oxygen species, and inhibits cytokine production and nuclear factor-kappa B (NF-κB) activation in colonic mucosa.
Olsalazine is a prodrug that is activated in the colon by bacterial azoreductases to release two molecules of 5-aminosalicylic acid (mesalamine), which locally inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene production, and exerts anti-inflammatory effects in the colonic mucosa.
Mesalamine 1000 mg rectally once daily at bedtime, or 500 mg rectally twice daily (morning and evening). Administered as suppository for ulcerative colitis.
500 mg orally twice daily, administered as two 250 mg capsules.
None Documented
None Documented
Terminal elimination half-life of mesalamine is approximately 0.5-2 hours; however, the N-acetyl metabolite has a half-life of 5-10 hours. Due to the sustained-release formulation, clinical effects persist beyond the plasma half-life.
Terminal elimination half-life of olsalazine is approximately 0.9 hours. The active metabolite, 5-ASA, has a half-life in the colon of 2-5 hours due to local retention; systemic half-life is short (0.6-1.4 hours).
Renal (approximately 20-30% as unchanged drug and metabolites, primarily N-acetyl-5-aminosalicylic acid); biliary/fecal (the remainder, with extensive enterohepatic circulation).
Primarily renal (80%), with fecal/biliary excretion up to 20% as olsalazine and metabolites (mainly 5-ASA).
Category C
Category C
Aminosalicylate
Aminosalicylate